• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Inflammation May Be the Culprit Behind Our Deadliest Diseases
In the early days of my medical residency, I met a man whom we’ll call Jason. He arrived to our emergency room on a holiday, nonchalant yet amiable, and complained of mild chest pain. Jason was tall and trim, with a strong South Boston accent and fingertips still faintly stained from his last home-improvement project. He was only 45 years old, but he looked much younger. He didn’t smoke, barely drank alcohol, and his cholesterol levels had always been normal. No one in his family had a history of heart disease. He asked us if we could work quickly—he wanted to be home for dinner with his daughters. [time-...
Source: TIME: Health - April 11, 2023 Category: Consumer Health News Authors: Shilpa Ravella Tags: Uncategorized freelance health Source Type: news

The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension
Conclusion: 6-MP partly reversed RV systolic pressure and RV afterload in established PAH. Together with the observed improved RV remodeling and cardiac function, 6-MP may be a promising intervention for PAH.
Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Sun, X.-Q., Kurakula, K., Happe, C., da Silva Goncalves Bos, D., Schalij, I., Vonk-Noordegraaf, A., de Man, F. S., Bogaard, H.-J., Goumans, M.-J. Tags: Pulmonary Circulation and Pulmonary Vascular Disease Source Type: research

Immune Modulatory Therapy Causing Acute Coronary Syndrome
We present a case of a 67-year-old male who presented with diffuse petechiae and was diagnosed with immune thrombocytopenic purpura with platelet count less than 10,000 per milliliter. Treatment was initiated with IVIG. When the third dose of IVIG was being administered he developed hypertensive urgency and non-ST segment elevation myocardial infarction. He was deemed not to be a candidate for cardiac catheterization and was treated conservatively. IVIG can cause major thrombotic adverse events such as deep vein thrombosis, myocardial infarction and stroke, which are attributed to thrombosis and hyperviscocity. Decreasing ...
Source: American Journal of Therapeutics - November 1, 2017 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

TRAFIP2 in Adverse Cardiac Remodeling Gene Regulation
TRAF3IP2 (TRAF3 interacting protein 2; previously known as CIKS or Act1) is a key intermediate in the normal inflammatory response and the pathogenesis of various autoimmune and inflammatory diseases. Induction of TRAF3IP2 activates IκB kinase (IKK)/NF-κB, JNK/AP-1, and c/EBPβ and stimulates the expression of various inflammatory mediators with negative myocardial inotropic effects. To investigate the role of TRAF3IP2 in heart disease, we generated a transgenic mouse model with cardiomyocyte-specific TRAF3IP2 overexpression (TRAF3IP2-Tg). Echocardiography, magnetic resonance imaging, and pressure-volume conductance cath...
Source: Journal of Biological Chemistry - September 8, 2016 Category: Chemistry Authors: Yariswamy, M., Yoshida, T., Valente, A. J., Kandikattu, H. K., Sakamuri, S. S. V. P., Siddesha, J. M., Sukhanov, S., Saifudeen, Z., Ma, L., Siebenlist, U., Gardner, J. D., Chandrasekar, B. Tags: Molecular Bases of Disease Source Type: research

Cardiac-restricted Overexpression of TRAF3 Interacting Protein 2 (TRAF3IP2) Results in Spontaneous Development of Myocardial Hypertrophy, Fibrosis, and Dysfunction Gene Regulation
TRAF3IP2 (TRAF3 interacting protein 2; previously known as CIKS or Act1) is a key intermediate in the normal inflammatory response and the pathogenesis of various autoimmune and inflammatory diseases. Induction of TRAF3IP2 activates IκB kinase (IKK)/NF-κB, JNK/AP-1, and c/EBPβ and stimulates the expression of various inflammatory mediators with negative myocardial inotropic effects. To investigate the role of TRAF3IP2 in heart disease, we generated a transgenic mouse model with cardiomyocyte-specific TRAF3IP2 overexpression (TRAF3IP2-Tg). Echocardiography, magnetic resonance imaging, and pressure-volume conductance cath...
Source: Journal of Biological Chemistry - September 8, 2016 Category: Chemistry Authors: Manjunath Yariswamy, Tadashi Yoshida, Anthony J. Valente, Hemanth Kumar Kandikattu, Siva S. V. P. Sakamuri, Jalahalli M. Siddesha, Sergiy Sukhanov, Zubaida Saifudeen, Lixin Ma, Ulrich Siebenlist, Jason D. Gardner, Bysani Chandrasekar Tags: Molecular Bases of Disease Source Type: research

Use of the Corus ® CAD Gene Expression Test for Assessment of Obstructive Coronary Artery Disease Likelihood in Symptomatic Non-Diabetic Patients
Conclusions The Corus CAD test has been extensively evaluated since it was first derived, including with two prospective multi-center trials. Given the scope of the deleterious effects of CAD and the considerable costs involved in diagnosing obstructive CAD, a blood test that can help in this determination is certainly valuable. The Corus CAD test promises to have an important role in this regard particularly if it continues to perform this well in larger, more diverse cohorts.
Source: PLOS Currents Evidence on Genomic Tests - August 26, 2013 Category: Genetics & Stem Cells Authors: Jose Vargas Source Type: research

Use of the Corus® CAD Gene Expression Test for Assessment of Obstructive Coronary Artery Disease Likelihood in Symptomatic Non-Diabetic Patients
Conclusions The Corus CAD test has been extensively evaluated since it was first derived, including with two prospective multi-center trials. Given the scope of the deleterious effects of CAD and the considerable costs involved in diagnosing obstructive CAD, a blood test that can help in this determination is certainly valuable. The Corus CAD test promises to have an important role in this regard particularly if it continues to perform this well in larger, more diverse cohorts.
Source: PLOS Currents Evidence on Genomic Tests - August 26, 2013 Category: Genetics & Stem Cells Authors: Jose Vargas Source Type: research